Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of once-weekly NNC0195-0092 versus placebo and daily Norditropin in adults with growth hormone deficiency
2013-002892-16Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of somapacitan in adult onset growth hormone deficiency (AGHD) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in truncal fat percentage. Started Sep 2014; status: completed.
02
Drugs
somapacitan
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on 2013-002892-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002892-16.